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Introduction
The heart relies on a complex network of cells to maintain ap-
propriate function. Cardiomyocytes, the contracting cells in the 
heart, exist in a three-dimensional network of endothelial cells, 
vascular smooth muscle, and an abundance of fibroblasts as well 
as transient populations of immune cells. Gap junctions electro-
chemically coordinate the contraction of individual cardiomyo-
cytes, and their connection to the extracellular matrix (ECM) 
transduces force and coordinates the overall contraction of the 
heart. Intracellularly, repeating units of actin and myosin form 
the backbone of sarcomere structure, the basic functional unit of 
the cardiomyocyte (Fig. 1). The sarcomere itself consists of 20 
proteins; however, more than 20 other proteins form connections 
between the myocytes and the ECM and regulate muscle con-
traction (Fig. 1 B). Given the complexity of the coordinated   
efforts of the many proteins that exist in multimeric complexes, 
dysfunction occurs when these interactions are disrupted.
Although the heart may functionally tolerate a variety of 
pathological insults, adaptive responses that aim to maintain 
function eventually fail, resulting in a wide range of functional 
deficits or cardiomyopathy. Although a multitude of intrinsic and 
extrinsic stimuli promote cardiomyopathies, the best described 
causes are the >900 mutations in genes expressed in the cardio-
myocyte (Fig. 1 B; Wang et al., 2010). Mutations in most of 
these genes cause a diverse range of cardiomyopathies, many 
with overlapping clinical phenotypes. Mutations in sarcomeric 
genes are usually inherited in an autosomal-dominant manner 
and are missense mutations that are incorporated into sarco-
meres (Seidman and Seidman, 2001). Thus far >400 mutations 
in 13 sarcomeric proteins including -myosin heavy chain   
(-MyHC), -cardiac actin, tropomyosin, and troponin have 
been associated with cardiomyopathy (www.cardiogenomics.
med.harvard.edu). Table I summarizes these mutated proteins.
There  are  several  examples  in  which  mutations  in  the 
same gene can cause different disease phenotypes (indicated in 
bold in Table I), suggesting that the position of the mutation 
within the gene influences the cardiac phenotype. Clinical phe-
notypes are also likely to be modified by sex hormones, diet, 
and polymorphisms in many genes including those involved in 
angiotensin signaling, thus complicating attempts to make pre-
dictive  correlations  between  specific  mutations  with  disease 
prognosis (Maron et al., 1995; Deinum et al., 2001; Stauffer   
et al., 2006). In fact, a modifier gene was identified in one strain 
of  mice  that  blocked  the  pathology  induced  by  a  mutated   
-MyHC (R403Q) in another strain of mice (Semsarian et al., 
2001). Characterization and mechanistic study of cardiomyopa-
thies are therefore challenging owing to the complex protein 
structures, the multitude of disease-causing mutations, and 
modulators of pathology.
A wide range of inherited and acquired cardiomyopathies 
has been described by the World Health Organization: hyper-
trophic  cardiomyopathy,  dilated  cardiomyopathy,  restrictive   
cardiomyopathy, and arrhythmogenic right ventricular cardio-
myopathy as well as a large group of unclassified cardiomyopa-
thies. Acquired cardiomyopathies induced by stress, diabetes, 
some chemotherapeutic agents, pregnancy, and alcohol intake, 
for example, represent a diverse class of cardiac disease (Bybee 
et al., 2004; Ro and Frishman, 2006; Dolci et al., 2008; Dobrin 
and  Lebeche,  2010;  Iacovoni  et  al.,  2010).  In  this  review,   
The heart exhibits remarkable adaptive responses to a 
wide array of genetic and extrinsic factors to maintain con­
tractile function. When compensatory responses are not 
sustainable, cardiac dysfunction occurs, leading to cardio­
myopathy. The many forms of cardiomyopathy exhibit 
a  set  of  overlapping  phenotypes  reflecting  the  limited 
range of compensatory responses that the heart can use. 
These  include  cardiac  hypertrophy,  induction  of  genes 
normally expressed during development, fibrotic deposits 
that replace necrotic and apoptotic cardiomyocytes, and 
metabolic disturbances. The compensatory responses are 
mediated by signaling pathways that initially serve to main­
tain  normal  contractility;  however,  persistent  activation   
of these pathways leads to cardiac dysfunction. Current   
research focuses on ways to target these specific path­
ways therapeutically.
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It is not yet clear whether clinical predictions can be made based 
solely on which functional domains carry mutations.
Cardiac dysfunction in HCM is attributable to initial in-
creases in heart mass and asymmetric interventricular septal 
thickening (Fig. 2, A and B; Maron et al., 1995; Marian, 2000; 
Wang et al., 2010). Histological hallmarks include an increase 
in cardiomyocyte size, disorganized arrangement of myocytes 
(myofibrillar disarray), and both perivascular and interstitial   
fibrosis, a common phenotype in many cardiomyopathies. Persis-
tent cardiac architectural changes in HCM can result in thinning 
of the ventricular walls, dilation of the ventricular chamber, and 
decreases in cardiac output that can lead to heart failure.
Dilated cardiomyopathy (DCM). DCM occurs in 1 
in 2,500 individuals in the United States and is considered the 
most prevalent form of cardiomyopathy because it is a common 
clinical outcome of many prolonged cardiac insults (Cregler, 
1989; Vikstrom et al., 1996). Enlargement of the ventricular 
chamber and thinning of the ventricular walls are the predomi-
nant phenotypes in this disease (Fig. 2 C). Loss of heart mass is 
highly correlated with heart failure and mortality; indeed, 50% 
we focus on inherited cardiomyopathies with known mutations 
in proteins expressed in the heart, describing their prevalence, 
pathology, and the cellular mechanisms of disease.
Inherited cardiomyopathies
Hypertrophic cardiomyopathy (HCM). HCM, which is 
inherited in an autosomal-dominant pattern in more than 50% 
of patients, occurs in 1 in 500 individuals with men affected 
nearly twice as much as women and is the leading cause of   
sudden cardiac death among young people in North America   
(Maron et al., 1984, 1995; Maron and Pelliccia, 2006).
Mutations in 13 sarcomeric proteins have been associated 
with HCM; those in -MyHC were the first to be identified in 
HCM and cause 30% of all cases (Kamisago et al., 2000; Peddy 
et al., 2006). Clinical phenotypes associated with these muta-
tions range from mild to severe, likely due to the locations of 
mutations in different functional domains as well as genetic 
modifiers and environmental stimuli. Most mutations are in the 
motor domain of myosin; however, disease-causing mutations 
in the rod region have also been identified (Buvoli et al., 2008). 
Figure 1.  Anatomy of the cardiac sarcomere. (A) Diagram of the basic organization of the sarcomere. The sarcomere forms the basic contractile unit in 
the cardiomyocytes of the heart. Thin filaments composed of actin are anchored at the Z line and form transient sliding interactions with thick filaments 
composed of myosin molecules. The M Line, I Band, and A Band are anatomical features defined by their components (actin, myosin, and cytoskeletal 
proteins) and appearance in polarized light. Titin connects the Z line with the M line and contributes to the elastic properties and force production of the 
sarcomere through its extensible region in the I Band. Coordinated shortening of the sarcomere creates contraction of the cardiomyocyte. (B) Representation 
of the major proteins of the cardiac sarcomere. Attachment to the ECM is mediated by costameres composed of the dystroglycan–glycoprotein complex 
and the integrin complex. Force transduction and intracellular signaling are coordinated through the costamere. The unique roles of each of these proteins 
are critical to appropriate function of the heart. T-cap, titin cap; MyBP-C, myosin-binding protein C; NOS, nitric oxide synthase.357 Cellular mechanisms of cardiomyopathy • Harvey and Leinwand
Table I. Cardiomyopathies, genetic causes, and cellular pathology
Disease Mutated gene Pathology
Hypertrophic cardiomyopathy Myosin binding protein C Increased heart mass
-Myosin heavy chain Left ventricular wall thickening
-Myosin heavy chain Increased cardiomyocyte size
-Tropomyosin Myofibrillar disarray
Troponin T Decreased volume of left ventricular chamber
-Cardiac actin Interstitial fibrosis
Troponin I Enlarged nuclei
Titin Ventricular wall stiffness
Myosin light chains Inflammation
Troponin C
Vinculin
Muscle LIM protein
Telothonin
Dilated cardiomyopathy -Myosin heavy chain Ventricular wall thinning
Desmin Ventricular chamber enlargement
N-cadherin Cardiomyocyte apoptosis
-Cardiac actin Interstitial fibrosis
Skeletal muscle myopathies Enlarged nuclei
-Tropomyosin 1 Ventricular wall stiffness
Muscle LIM protein -sarcoglycan Inflammation
Lamin A/C
TAZ (G4.5)
Titin
Phospholamban
Vinculin
Troponin I
Troponin T2
SCN5A
Presenilin 1 & 2
Troponin C
-Cardiac actinin
Plakoglobin
Restrictive cardiomyopathy Troponin I Ventricular wall stiffness
Desmin Apoptosis
-Cardiac actin Fibrosis
Skeletal muscle myopathies Myofibrillar disarray
Troponin T
-Myosin heavy chain
Left ventricular noncompaction TAZ (G4.5) Trabeculated ventricular walls
-Dystrobrevin Noncompaction of ventricular endocardium
FKBP12 Necrotic myocytes
-Myosin heavy chain Fibrosis
-Cardiac actin Myofibrillar disarray
Cardiac troponin
Arrhythmogenic right ventricular cardiomyopathy Plakophilin-2 Right ventricular dilation
Junctional plakoglobin Right ventricular fibrosis
Desmocollin-2 Fibrofatty infiltration
Desmoglein-2 Apoptosis
Desmoplakin
Muscular dystrophy–associated cardiomyopathy Dystrophin Left ventricular hypertrophy or dilation
Sarcoglycan Fibrosis
Dystroglycan Apoptosis
Dystrobrevin
Bold: mutations that are common to multiple forms of cardiomyopathy.JCB • VOLUME 194 • NUMBER 3 • 2011   358
Arrhythmogenic  right  ventricular  cardiomy-
opathy (ARVC). ARVC occurs in 1 in 5,000 individuals 
and primarily affects adults (Basso et al., 2009). However, ARVC 
is also an important cause of death among young people, account-
ing for 20% of deaths occurring in individuals under 30 years 
old (Shen et al., 1995). ARVC is inherited in an autosomal-
dominant or recessive pattern in 50% of cases often with in-
complete penetrance, so unknown genetic or environmental 
modifiers are predicted (Basso et al., 2009).
Mutations in proteins that comprise the cardiac desmo-
some, a junctional complex that mechanically couples neigh-
boring cardiomyocytes to coordinate contractile activity, account 
for most inherited cases of ARVC (Yang et al., 2006). Disrup-
tions in desmosome stability cause structural and functional   
alterations and are associated with cardiomyocyte apoptosis 
(Yamaji et al., 2005). Adipose and fibrotic tissue that replace 
cardiomyocytes are a hallmark of ARVC, primarily in the right 
ventricle; however, left ventricular involvement is common in 
later stages of the disease (Corrado et al., 1997). The right ven-
tricle enlarges as myocyte loss progresses, causing a reduction 
in blood volume pumped from the heart and arrhythmias.
Left ventricular noncompaction cardiomyopa-
thy (LVNC). LVNC, a recently delineated form of cardio-
myopathy, is defined anatomically by deep trabeculations that   
create a spongiform appearance of the ventricular walls (Fig. 2 D; 
Chin et al., 1990). Clinically, patients present with depressed 
systolic and diastolic dysfunction, left and right ventricular   
hypertrophy, arrhythmias, and, in some cases, conduction block.   
Familial forms with autosomal-dominant or X-linked transmis-
sion account for up to 50% of all LVNC cases (Chin et al., 1990; 
Sasse-Klaassen et al., 2003). The mechanisms responsible for 
pathology are poorly defined, but indirect evidence suggests that 
malformation of the myocardium contributes to functional ab-
normalities in the adult (Yousef et al., 2009). During develop-
ment, the loose network of fibers that form the myocardium 
becomes compacted between the fifth and eighth prenatal weeks. 
In patients with LVNC, a normal pattern of compaction occurs 
in the outer band of the myocardium, but an abnormal non-
compacted region within the inner (endocardial) layer localized 
mainly in the apical and midventricular regions of the heart is 
also observed (Fig. 2 D; Chin et al., 1990; Ritter et al., 1997; 
Freedom et al., 2005) . Similarities among LVNC, HCM, and 
DCM, likely caused by mutations in the same gene (-MyHC, 
for example), motivate differential diagnosis criteria aimed at 
better  defining  this  syndrome  (Weiford  et  al.,  2004;  Kaneda   
et al., 2008).
of those diagnosed with DCM die within five years of becoming 
symptomatic (Michels et al., 1992; Grogan et al., 1995).
Although DCM can occur secondary to systemic pathol-
ogy, approximately one half of cases are not associated with   
a systemic cause (idiopathic DCM). Among these cases, about 
one third of patients have a family history of DCM (familial 
DCM) that is transmitted autosomally (recessive and dominant), 
through maternal mitochondrial DNA, or as an X-linked muta-
tion (Berko and Swift, 1987; Keeling et al., 1995; Mestroni   
et al., 1999). In contrast to HCM, which is almost exclusively 
associated with mutations in sarcomeric proteins, familial DCM 
is primarily associated with mutations in cytoskeletal proteins 
(Table I). These and other proteins that connect the sarcomere to 
the ECM form the mechanotransduction apparatus that allows 
cardiomyocytes to sense and respond to changes in contractility. 
Disruption of components of this apparatus therefore prevents 
the heart from productively responding to both extrinsic and   
intrinsic stressors.
Restrictive cardiomyopathy (RCM). RCM is the 
least common but most lethal form of cardiomyopathy (Davis   
et al., 2007). Causes of RCM are extremely variable and include 
induced and genetic initiators as well as idiopathic etiologies. 
Idiopathic RCM occurs in the absence of other pathology,   
although it can be associated with skeletal muscle myopathies 
(Katritsis et al., 1991). Injury to the heart caused by radiation, 
scarring after heart surgery, infection, or diseases such as amy-
loidosis can also cause RCM. Recently, mutations in the sarco-
meric protein troponin I, which participates in the regulation of 
calcium-mediated actin–myosin interactions and contractility, 
were associated with a familial form of the disease, and it is 
now recognized as the primary disease-causing mutation in   
familial RCM (Mogensen et al., 2003). Mutations in other sar-
comeric proteins such as cardiac desmin, -cardiac actin, and 
-MyHC as well as mutations that have been implicated in 
HCM have been described in RCM patients (Karam et al., 2008; 
Parvatiyar et al., 2010).
Unlike in HCM, alterations in tissue flexibility occur in RCM 
in the absence of changes in ventricular myofibrillar arrangement 
and gross abnormalities (Huang and Du, 2004). RCM is, there-
fore, characterized by increased stiffness of the myocardium 
that causes increased pressure in one or both ventricles. Ventricu-
lar relaxation is impaired, similar to the phenotype observed in 
HCM, and the atria then enlarge in response to the increased pres-
sure in some patients (Parvatiyar et al., 2010). The restrictive   
phenotype is common to RCM and some cases of HCM, empha-
sizing the need for more precise diagnostic criteria.
Figure  2.  Gross  pathology  associated  with  cardiomy-
opathies. Illustrations depicting (A) a healthy heart with 
normal wall thicknesses and chamber volumes and (B) hy-
pertrophic  cardiomyopathy.  Asymmetric  hypertrophy  of 
the interventricular septum as well as the left ventricular 
posterior wall and apex is present. (C) Dilated cardio-
myopathy. Thinning of the ventricular walls enlarges the 
interior dimensions of the ventricular chamber. The left 
and right atria are also enlarged due to impaired ven-
tricular relaxation. (D) Left ventricular noncompaction. Tra-
beculated ventricular walls create a spongy appearance, 
prominent in the left ventricular wall. Ao, aorta; LA, left 
atrium; LV, left ventricle; RV, right ventricle.359 Cellular mechanisms of cardiomyopathy • Harvey and Leinwand
Cardiac hypertrophy is attributable to structural altera-
tions within individual cardiomyocytes. The addition of sarco-
meres  in  parallel  is  an  adaptive  response  to  increase  force 
production in stressed cells. Increased myocyte width (concen-
tric hypertrophy; Fig. 3, A and B) correlates with compensatory 
ventricular hypertrophy, a hallmark of HCM. In HCM, how-
ever, concentric hypertrophy causes a distortion of the cardio-
myocyte alignment, which may affect contractility in the heart 
(Seidman and Seidman, 2001). There remains no clear consen-
sus on whether cardiomyocyte hypertrophy is truly compen-
satory or merely a component in the pathway to heart failure. 
However,  when  hypertrophic  growth  in  a  myosin  model  of 
HCM was blocked by constitutive activation of glycogen syn-
thase kinase 3 (GSK3), all male animals died, suggesting 
that the initial phases of hypertrophy are indeed compensatory 
(Luckey et al., 2009). Persistent hypertrophy with disease is 
positively associated with the development of heart failure.   
After an initial phase of compensatory hypertrophy, addition of 
sarcomeres to ventricular cardiomyocytes increases length- 
to-width ratios, which leads to decreased force production. In-
creased  myocyte  length  produced  by  end-to-end  addition  of 
sarcomeres (eccentric hypertrophy; Fig. 3, C and D) is associated 
with ventricular dilation in DCM and with advanced HCM.
Fetal  gene  program. In cardiomyopathy, induction 
of genes normally expressed during embryogenesis occurs   
including  natriuretic  factors,  -MyHC,  and  -skeletal  actin   
(Kuwahara et al., 2003). Natriuretic proteins secreted by cells   
in the atria and ventricles, atrial natriuretic factor (ANF) and 
brain natriuretic peptide (BNP), respectively, induce diuresis and   
vasodilation, which are capable of reducing blood volume   
and pressure in response to increased wall stress. These factors 
are up-regulated in response to transient increases in blood pres-
sure. However, in cardiomyopathy, transcription and secretion 
are chronic.
ANF  expression  is  increased  in  atrial  myocytes  when 
hearts exhibit diastolic dysfunction, which increases tension on 
the walls of the atria, and is released by ventricular myocytes 
when there is increased pressure on the ventricular walls in 
cardiomyopathy (Rodeheffer et al., 1986; Edwards et al., 1988). 
Ventricular hypertrophy causes excessive stress in the ventricu-
lar wall during contraction, which also serves as a stimulus for 
release of BNP (Kinnunen et al., 1993). Induced expression of 
these genes, therefore, implies a cardioprotective mechanism 
that indirectly attempts to normalize pathological changes that 
affect the heart. Some evidence suggests that these genes may 
be anti-hypertrophic to prevent overgrowth of the organ in re-
sponse to stress (Silberbach et al., 1999).
Myosin isoform shift. In the face of a wide variety of 
pathological insults, up-regulation of the -MyHC isoform   
occurs. Myosin exists as two heavy chains and two pairs of   
light chains. Cardiac muscle contains two isoforms of MyHC,   
-MyHC and -MyHC, which are expressed in species-specific 
proportions in the heart. -MyHC accounts for more than 90% 
of the MyHC in the adult human ventricle. The proportion of 
these isoforms in the heart is tightly regulated, such that up- 
regulation of -MyHC expression with a concomitant decrease 
in -MyHC in the hearts of humans and rodents is a sensitive 
Cardiomyopathies  associated  with  muscular 
dystrophies. Muscular dystrophies, caused by autosomal-
recessive mutations in proteins that anchor the sarcomere to the 
ECM, are a heterogeneous group of skeletal muscle disorders. 
Incidence of cardiac involvement among patients with muscu-
lar dystrophies varies and is dependent upon the disease-causing 
mutations. Although Duchenne and Becker muscular dystro-
phies are X-linked, up to 18% of female carriers that do not   
exhibit skeletal muscle disease exhibit heart failure, illustrating 
that even subtle disruption of the interactions between the sar-
comere and ECM can impart cardiac dysfunction (Hoogerwaard 
et al., 1999).
Identification of disease-causing mutations in the heart 
has contributed to the delineation of many phenotypically similar 
cardiomyopathies. However, much work remains in elucidating 
the specific cellular mechanisms of disease. In the past decade, 
resources available to study cardiomyopathies at the cellular 
level have evolved to allow the study of mechanisms of patho-
genesis using a variety of experimental approaches including in 
vitro biochemistry, cell biology, and animal models (Flavigny 
et al., 1999; Haq et al., 2000; Maass and Buvoli, 2007). These 
studies have revealed the roles of a variety of cell types in the 
development of cardiomyopathy. In addition to cardiomyocyte-
mediated effects, nonmyocytes induce functional changes in 
cardiomyocytes and in the structural properties of the ECM. 
Deposition  of  collagen  by  fibroblasts,  for  example,  creates   
fibrotic scars that stiffen the heart tissue and impede normal   
cardiomyocyte  contractility.  In  the  sections  that  follow,  we 
present an overview of the cellular pathology mediated by car-
diac cells with an emphasis on the cardiomyocyte, whose   
responses to intrinsic and extrinsic insults most profoundly affect 
cardiac function.
Altered cardiomyocyte cell biology  
in cardiomyopathy
Different classifications of cardiomyopathy exhibit a subset of 
overlapping symptoms, emphasizing the limited range of cellu-
lar  responses  in  the  cardiomyocyte  (Table  I).  Alterations  in 
gene expression patterns, changes in cellular morphology, and 
metabolic shifts in cardiomyocytes initially improve or main-
tain function in the early stages of many forms of cardiomyopa-
thy. An exception to this is DCM, which does not appear to 
progress through this initial series of compensatory responses. 
Patients with DCM exhibit a dilated phenotype that decompen-
sates rapidly when patients become symptomatic, similar to 
end-stage heart failure HCM.
Cardiomyocyte  hypertrophy. In response to al-
tered contractility or physiological stress, ventricular cardio-
myocytes increase in size to keep pace with increased functional 
demand, thus increasing the thickness of the walls but reduc-
ing interior dimensions of the ventricular chambers. Regard-
less of the initial stimulus, cardiac hypertrophy is thought to 
be compensatory as it normalizes increased stress in the ven-
tricular wall and augments the contractile capacity of the 
heart.  The  development  of  hypertrophy  therefore  implies   
an anatomical adaptation that does not explicitly signify a 
disease state.JCB • VOLUME 194 • NUMBER 3 • 2011   360
disruption of excitation–contraction coupling between cardio-
myocytes and increased stiffness of the myocardium, and leads 
to  decreased  contractility  in  the  heart  (Menon  et  al.,  2009).   
Fibrosis is primarily produced by resident fibroblasts in the heart; 
however, there is evidence for collagen production by cardio-
myocytes (Schram et al., 2010).
Recent studies support a link between sarcomere muta-
tions and gene expression changes in nonmyocytes that pro-
motes production of fibrosis. Increased transcription and release 
of TGF- in the hearts of mice expressing HCM-causing muta-
tions in -MyHC (R403Q, R719W) activate nonmyocytes and 
promote increased focal and interstitial fibrosis (Teekakirikul   
et al., 2010). Interference with the development of excessive   
fibrosis in the hearts of patients with cardiomyopathy could rep-
resent a promising therapy to reduce the functional deficits that 
result from disease-causing mutations in cardiomyocytes.
Alteration  in  metabolic  substrate  utilization. 
In the healthy heart, phosphocreatine is the main reserve source 
of ATP during acute stress. As pathogenesis progresses in car-
diomyopathy, the demand for ATP increases, and the levels of 
phosphocreatine are progressively depleted (Ingwall and Weiss, 
2004; Smith et al., 2006). This reduction in energy-rich re-
sources forces the heart to favor alternative energy substrates 
marker of early cardiomyopathy (Lowes et al., 1997; Miyata   
et al., 2000). This response may be adaptive, as -MyHC exhib-
its lower ATPase activity resulting in improved ATP use, and 
may be a requirement in the presence of mutations that reduce 
efficiency of contractility. However, features of -MyHC, which 
exhibits slower filament sliding velocity, may contribute to   
pathology (Schwartz et al., 1981).
Contractility of the heart is inversely proportional to the 
amount of expression of -MyHC (Palmiter et al., 1999; Herron 
and McDonald, 2002). Titration of -MyHC expression in adult 
ventricular cardiomyocytes results in a dose-dependent reduc-
tion in sarcomere shortening and velocity, independent of Ca
2+ 
handling (Herron et al., 2007). The shift toward -MyHC in the 
pathological heart may contribute to the decreased myocyte short-
ening and prolonged relaxation of cardiomyocytes observed 
during the transition from compensatory hypertrophy to heart 
failure (Nagata et al., 1998).
Fibrosis. The development of interstitial and perivascu-
lar fibrosis is a hallmark of pathology in the heart. Focal fibro-
sis, composed primarily of collagen types I and III, occurs in the 
early stages of cardiomyopathy, but over time fibrosis increases 
and directly compromises the function of cardiomyocytes. The 
presence of collagen-rich regions in the myocardium causes 
Figure 3.  Isolated cardiomyocytes exhibiting hypertrophy and heart failure. (A) Untreated adult ventricular cardiomyocyte demonstrating normal brick-like 
morphology. (B) An adult ventricular cardiomyocyte treated with endothelin-1 precursor protein exhibiting significant concentric hypertrophy. The cardio-
myocyte is decreased in length and increased in width, consistent with the phenotype observed in human cardiomyocytes with concentric hypertrophy.   
A and B are reproduced from Gupta et al. (2005) with permission from Elsevier. (C) Cardiomyocyte isolated from a healthy human heart. (D) Cardiomyo-
cyte isolated from the heart of a patient in heart failure. Increased length and decreased width are characteristic of eccentric hypertrophy. C and D are 
reproduced from Ohler et al. (2009) with permission from Brian O’Rourke.361 Cellular mechanisms of cardiomyopathy • Harvey and Leinwand
acute changes that might initiate other longer-term responses in 
the heart but are nonetheless important to consider when exam-
ining possible transducers of systemic and tissue alterations to 
the cardiomyocyte.
Changes in wall stress induce signaling pathways that are 
associated  with  the  development  of  cardiac  pathology.  The 
many intracellular signaling pathways that mediate responses to 
increased demand on the heart have been extensively reviewed 
elsewhere  (Force  et  al.,  1999;  Molkentin  and  Dorn,  2001; 
Heineke and Molkentin, 2006). Here, we focus on pathways 
that are intimately involved in pathogenesis (Fig. 4). Although 
their effects in compensatory responses early in pathology ini-
tially increase function by promoting growth and contractility, 
persistent responses eventually compromise function.
Akt signaling. Akt, the major effector of phosphoinosi-
tide 3-kinase (PI3K) signaling, mediates many processes important 
to cardiac adaptation including protein synthesis, inhibition of 
apoptosis, and metabolism. Despite clear beneficial effects of 
acute Akt activation, chronic activation of the PI3K/Akt path-
way causes cardiomyopathy. The divergent effects of activated 
Akt are dependent on the length of time Akt is activated and the 
initiator of the pathway. Mice expressing constitutively acti-
vated (myristoylated) Akt have hearts and cardiac myocytes 
that are approximately twofold larger than littermate controls 
and are protected from ischemia reperfusion injury. However, 
other founder mice expressing the transgene die with cardiac 
enlargement and presumed heart failure (Matsui et al., 2002). 
Also, a conditional mutant with activated Akt1 exhibits revers-
ible hypertrophy with two weeks of transgene expression but 
irreversible hypertrophy with fibrosis and reduced angiogenesis 
when expressed for six weeks (Shiojima et al., 2005). There-
fore, activation of Akt signaling increases cell size and contrac-
tile efficiency in the face of acute intensification of functional 
demand; however, the temporal activation of this pathway de-
termines whether the adaptive effects are maintained produc-
tively (Matsui et al., 2002; O’Neill and Abel, 2005).
Downstream of Akt is the kinase GSK-3, which nega-
tively regulates cardiomyocyte size. GSK-3 is largely un-
phosphorylated and constitutively active in the healthy heart; 
phosphorylation of GSK-3 by Akt inactivates it. Overexpres-
sion of activated GSK-3 causes reduced heart size and de-
creased hypertrophy in response to pathological stimuli (Haq   
et al., 2000; Michael et al., 2004). In genetic models of HCM 
with mutations in sarcomeric proteins, GSK-3 is inactivated, 
consistent with hypertrophy in these models and demonstrating 
downstream alterations in the Akt signaling cascade (Stauffer   
et al., 2006; Luckey et al., 2009).
G protein signaling. Pathological stimuli that induce 
increased pressure or mechanical stretch in the heart promote 
release of several paracrine and autocrine factors including ad-
renergic factors, angiotensin II, and endothelin (ET1), which 
each activate G protein–coupled receptor (GPCR) signaling.   
G protein subunits serve as effectors for downstream signaling 
cascades and modulate cardiac adaptation, namely those pro-
cesses intended to increase force production like cardiomyocyte 
hypertrophy. Mechanical stretch of adult ventricular cardiomyo-
cytes and administration of Gq activating agents (norepinephrine, 
during  prolonged  stress  mediated  by  exogenous  cardiotoxic 
stimuli or contractile dysfunction caused by mutated sarcomeric 
proteins. During the initial compensatory stages of cardiomyopa-
thy, substrate utilization favors free fatty acids, which yield 
about three times more ATP than glucose but require more   
oxygen to metabolize, making it a more lucrative but less effi-
cient means to produce energy (Ashrafian and Frenneaux, 2007; 
Neubauer, 2007).
In  the  failing  heart,  as  in  DCM  and  end-stage  HCM,   
energy substrate utilization in the heart shifts from fatty acid 
oxidation to glucose utilization, a less efficient means of pro-
ducing energy (Stanley et al., 1997; Kalsi et al., 1999; Dávila-
Román et al., 2002). A proposed mechanism for this transition 
from compensatory to decompensatory cardiac hypertrophy is 
excessive cardiac growth without adequate coronary angio-
genesis. A mildly hypoxic state up-regulates genes that facilitate 
utilization of glucose instead of fatty acids (Huang et al., 2004). 
This is supported by studies in the developing heart in which 
exposure to the oxygen-rich postnatal environment at birth cor-
relates with a dramatic shift in metabolic enzyme isoforms to 
use fatty acids as an energy substrate (Lopaschuk et al., 1991). 
Indeed, hypertrophy induced by volume overload in newborns 
delays this shift (Kantor et al., 1999). Expression and activity of 
enzymes that mediate fatty acid use, such as medium-chain 
acyl-CoA dehydrogenase and peroxisome proliferator-activated 
receptor-, are down-regulated in the failing adult heart to re-
semble expression in the fetal heart (Sack et al., 1996). There-
fore, the heart progresses through several stages of metabolic 
changes as it enters heart failure: the increased use of fatty acids 
during compensation and a shift to glucose utilization as the 
heart decompensates.
Sensing and responding to cellular stress
The cellular responses observed in cardiomyopathies arise from 
the  detection  of  functional  changes  mediated  primarily  by 
ECM–sarcomere connections and collectively aim to maintain 
sufficient contractile force and prevent progression to heart   
failure. Signaling pathways initiated by mechanotransduction 
in the cardiomyocyte initially serve to reduce blood volume, 
add sarcomeres to increase contractile capacity, and shift meta-
bolic processes to those that favor the utilization of substrates 
that yield more energy (lipids).
Mechanotransduction and signaling in the car-
diomyocyte. The responses of cardiomyocytes to systemic 
stress or genetic abnormalities are modulated by mechanosensi-
tive  mechanisms  within  the  cardiomyocyte  (Molkentin  and 
Dorn,  2001;  Seidman  and  Seidman,  2001;  Frey  and  Olson, 
2003). A complex network of proteins that connects the sarco-
mere to the ECM forms the basis of the mechanotransduction 
apparatus. For example, components of the costamere complex, 
which form the connection between the sarcomere and the   
ECM via integrins, initiate intracellular signaling and subse-
quently alter contractile properties and transcriptional regula-
tion in response to membrane distortion. Mechanosensitive ion 
channels are also implicated in signal initiation in response to 
systemic stress (Le Guennec et al., 1990; Zhang et al., 2000;   
de Jonge et al., 2002). These channels are likely responsible for JCB • VOLUME 194 • NUMBER 3 • 2011   362
then translocates into the nucleus. Calcineurin activation exacer-
bates hypertrophic signals and expedites the transition to a de-
compensatory state. Indeed, cardiac-specific overexpression of 
calcineurin or NFAT leads to significant cardiac hypertrophy that 
progresses rapidly to heart failure (Molkentin et al., 1998). Ad-
ministration of antagonists of calcineurin attenuates the hypertro-
phic response of neonatal rat ventricular myocytes to stimuli such 
as phenylephrine (PE) and angiotensin II (Taigen et al., 2000).
Apoptotic  pathways. Apoptosis has recently been 
shown to play a major role in cardiac disease (Gill et al., 2002). 
Adult cardiomyocytes are terminally differentiated, so cell loss 
is detrimental to cardiac function. Additionally, when cardio-
myocytes are lost, deposition of collagen occurs. Ultimately, 
this decreases heart compliance, increases cardiomyocyte wall 
stress, and impairs ventricular relaxation.
Apoptosis has been demonstrated in HCM and DCM as 
evidenced by activated apoptotic pathway components and cas-
pase activity (Narula et al., 1996; Olivetti et al., 1997; Akyürek 
et al., 2001). Many of the signaling pathways activated with   
increased cardiomyocyte stretch are implicated in regulation   
of apoptosis, including Akt and adrenergic stimulation. Several 
groups have demonstrated that hyperactivation of -adrenergic 
signaling  pathways  and  cytochrome  c  release  from  mito-
chondria are associated with increased apoptosis and fibrosis   
(Communal et al., 1998; Geng et al., 1999; Iwai-Kanai et al., 
1999; Narula et al., 1999). Additionally, evidence for increased 
signaling  through  Fas  receptors  by  up-regulation  of  TNF  is 
common in heart failure, and the degradation of inhibitors of 
Fas receptor signaling such as cFlip is another mechanism by 
which apoptosis may occur (Krown et al., 1996; Torre-Amione 
et al., 1996). Studies from human heart biopsies reveal that 
greater cell loss is observed in the early stages of cardiomyopathy, 
suggesting that anti-apoptotic pathways are up-regulated after 
angiotensin II) in neonatal rat ventricular myocytes specifically 
induce  hypertrophy  (Sadoshima  and  Izumo,  1993;  Kojima   
et al., 1994). Each of the agents that activate Gq in neonatal   
rat ventricular myocytes also induces activation of phospho-
lipase C and hypertrophy (Simpson et al., 1982; Knowlton et al., 
1993; Adams et al., 1996; Sakata et al., 1998). In agreement with 
these data, Gq attenuation decreases hypertrophy, cardiac re-
modeling, and functional deficits in response to pressure overload 
in mice (Esposito et al., 2001). Transgenic mice overexpressing 
Gq exhibit cardiac growth similar to that induced by pressure 
overload, independent of this stimulus (D’Angelo et al., 1997; 
Sakata et al., 1998). The hearts of these mice also exhibit some 
qualities of pathological hypertrophy including left ventricular 
dysfunction and induction of the fetal gene program indicative 
of cardiomyopathy (D’Angelo et al., 1997; Sakata et al., 1998).
Ca
2+ regulation and calcineurin signaling. Ca
2+ 
concentrations inside the cardiomyocyte are critically important 
to actin–myosin interactions. Ca
2+ is sequestered within the   
sarcoplasmic reticulum and the sarcomere itself, which serves 
as an intracellular reserve that is released in response to electrical 
stimulation of the cardiomyocyte. After contraction, sarco/endo-
plasmic reticulum Ca
2+-ATPase sequesters the Ca
2+ back into 
the sarcoplasmic reticulum to restore Ca
2+ balance. There is a 
clear correlation between force production and perturbation of 
Ca
2+ regulation, alterations of which might directly induce path-
ological, anatomical, and functional alterations that lead to heart 
failure via activation of GPCRs (Minamisawa et al., 1999).
Ca
2+ in the cytosol can be increased to modulate sarcomere 
contractility by signaling through Gq recruitment and activation 
of PLC. Ca
2+ released from the sarcoplasmic reticulum activates 
calmodulin, which phosphorylates calcineurin, a serine/threonine 
phosphatase. Upon activation, calcineurin interacts with and de-
phosphorylates nuclear factor of activated T cells (NFAT), which 
Figure  4.  Signaling  pathways  associated  with 
cardiac hypertrophy. Although many pathways are 
associated with cardiomyopathy, up-regulation of 
transcription and induction of apoptosis are major 
mediators  of  pathogenic  responses  in  the  heart. 
The GPCR-associated pathway (dark red) can be 
activated by ET-1 and AngII, which are released 
in response to reduced contractility, and mediates 
contractile adaptation through increased calcium 
release from the sarcoplasmic reticulum. Increased 
intracellular calcium activates calmodulin and in-
duces activation of the transcription factor MEF2. 
Incorporation  into  the  sarcomere  of  mutant  pro-
teins  that  exhibit  reduced  ATP  efficiency  inhibits 
the sequestration of calcium from the cytosol and 
further enhances increases in intracellular calcium 
concentration. GPCR signaling is also associated 
with activation of the Akt signaling pathway (light 
green) that induces fetal gene expression and the 
cardiac hypertrophic response through inhibition of   
GSK3. Apoptotic pathways (light blue) are induced 
by cytochrome c (CytC) release from mitochondria 
and activation of death receptors (like FasR) by cyto-
kines such as TNF. Calcium overload and myocyte 
loss significantly contribute to reduced contractility in 
many forms of cardiomyopathy. ET-1, endothelin-1; 
HDAC, histone deacetylase; NFAT, nuclear factor 
of activated T cells; MEF-2, myocyte enhancer fac-
tor 2; SERCA, sarco/endoplasmic reticulum calcium-
ATPase; cFLIP, cellular FLICE-inhibitory protein; AngII, 
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cell loss has been initiated (Akyürek et al., 2001). It follows that 
tight regulation of apoptosis is required for proper cardiac adap-
tation and that disruption of these pathways can have irrevers-
ible consequences in the heart.
Summary
Advances in molecular techniques have vastly improved the un-
derstanding of mechanisms responsible for cardiac dysfunction 
in cardiomyopathies. It is clear that mutant proteins in cardio-
myocytes can perturb cardiac function whether they occur in 
the contractile apparatus or in the mechanosensitive complexes. 
Alterations in cardiomyocyte function initiate cascades of cel-
lular responses that attempt to compensate for these insults by 
normalizing functional parameters in the cells. However, per-
sistent responses at the cellular level lead to organ-wide altera-
tions that are highly correlated with sudden cardiac death and 
heart failure. Much remains to be learned about precise mecha-
nisms that modulate the transition between compensatory re-
sponses in the heart and the development of heart failure.
Despite these challenges, basic studies of the processes 
that mediate cellular responses to cardiac stress have allowed the 
development of therapeutics for some cardiomyopathies that in-
clude drugs that decrease blood pressure and heart rate (angio-
tensin II receptor antagonists, Ca
2+ channel blockers) to reduce 
the strain on the ventricular walls. Implantable devices that regu-
late the synchronization of contraction also reduce the progres-
sion of cardiomyopathies (Rose et al., 2001). Although there 
exist no treatments to directly address the causes of inherited 
cardiomyopathies, cell transplantation, gene therapy, small inter-
fering RNAs, and microRNAs remain on the horizon of inno-
vative treatments that address the causes rather than reduction of 
symptoms of cardiomyopathies. Utilization of animal and cellu-
lar models to further probe the mechanisms of cardiomyopathy 
and demonstrate efficacy of drugs that specifically target disease-
causing  pathways  hold  promise  that  further  reduction  in  the 
mortality associated with cardiomyopathies can be achieved.
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